Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia.

Published

Journal Article

The survival of patients with acute leukemia who do not achieve a remission with primary therapy is very poor. High-dose chemoradiotherapy followed by allogeneic bone marrow transplantation (BMT) has been shown to be effective therapy for patients with acute and chronic leukemia. Therefore, we determined the long-term disease-free survival of patients who did not achieve a remission and were then treated with high-dose therapy and bone marrow allografting from matched sibling donors. Twenty-one patients (median age, 28 years) who did not achieve a remission with induction chemotherapy were subsequently treated with allogeneic BMT. After BMT, 90% achieved a complete remission. Six died of complications of the therapy, and six patients relapsed between 27 and 448 days after BMT. Nine patients (43%; median age, 25 years) are alive between 556 and 4,174 days after BMT. The cumulative probability of disease-free survival at 10 years is 43%. This study suggests that allogeneic BMT can be an effective therapy to achieve long-term control of acute leukemia, even in those patients who do not achieve a remission with primary therapy.

Full Text

Duke Authors

Cited Authors

  • Forman, SJ; Schmidt, GM; Nademanee, AP; Amylon, MD; Chao, NJ; Fahey, JL; Konrad, PN; Margolin, KA; Niland, JC; O'Donnell, MR

Published Date

  • September 1, 1991

Published In

Volume / Issue

  • 9 / 9

Start / End Page

  • 1570 - 1574

PubMed ID

  • 1875218

Pubmed Central ID

  • 1875218

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/JCO.1991.9.9.1570

Language

  • eng

Conference Location

  • United States